EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Point‐of‐care Analysis for Non‐invasive Diagnosis of Oral cancer ( PANDORA ): A technology‐development proof of concept diagnostic accuracy study of dielectrophoresis in patients with oral squamous cell carcinoma and dysplasia

Michael P Hughes, Fatima H Labeed, Kai F Hoettges, Stephen Porter, Valeria Mercadante iD, Nicholas Kalavrezos, Colin Liew, James A McCaul, Raghav Kulkarni, James Cymerman, Cyrus Kerawala, Julie Barber und 2 weitere

Journal of Oral Pathology & Medicine · 2023

DOI: 10.1111/jop.13417 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Oral Pathology & Medicine, 2023. Verfasst von Michael P Hughes und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical Engineering, Khalifa University, Abu Dhabi, United Arab Emirates. Hauptthemen laut MEDLINE: Mouth Neoplasms, Carcinoma, Squamous Cell, Head and Neck Neoplasms. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Invention for Innovation Programme, National Institute for Health Research, UCLH Biomedical Research Centre.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Delays in the identification and referral of oral cancer remain frequent. An accurate and non‐invasive diagnostic test to be performed in primary care may help identifying oral cancer at an early stage and reduce mortality. Point‐of‐care Analysis for Non‐invasive Diagnosis of Oral cancer (PANDORA) was a proof‐of‐concept prospective diagnostic accuracy study aimed at advancing the development of a dielectrophoresis‐based diagnostic platform for oral squamous cell carcinoma (OSCC) and epithelial dysplasia (OED) using a novel automated DEPtech 3DEP analyser.

Methods

The aim of PANDORA was to identify the set‐up of the DEPtech 3DEP analyser associated with the highest diagnostic accuracy in identifying OSCC and OED from non‐invasive brush biopsy samples, as compared to the gold standard test (histopathology). Measures of accuracy included sensitivity, specificity, positive and negative predictive value. Brush biopsies were collected from individuals with histologically proven OSCC and OED, histologically proven benign mucosal disease, and healthy mucosa (standard test), and analysed via dielectrophoresis (index test).

Results

40 individuals with OSCC/OED and 79 with benign oral mucosal disease/healthy mucosa were recruited. Sensitivity and specificity of the index test was 86.8% (95% confidence interval [CI], 71.9%–95.6%) and 83.6% (95% CI, 73.0%–91.2%). Analysing OSCC samples separately led to higher diagnostic accuracy, with 92.0% (95% CI, 74.0%–99.0%) sensitivity and 94.5% (95% CI, 86.6%–98.5%) specificity.

Conclusion

The DEPtech 3DEP analyser has the potential to identify OSCC and OED with notable diagnostic accuracy and warrants further investigation as a potential triage test in the primary care setting for patients who may need to progress along the diagnostic pathway and be offered a surgical biopsy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Mouth NeoplasmsCarcinoma, Squamous CellHead and Neck NeoplasmsHumansSquamous Cell Carcinoma of Head and NeckProspective StudiesPoint-of-Care SystemsBiomarkers, TumorHyperplasiaTechnology

Stichwörter der Autor:innen

diagnosisdielectrophoresisoral canceroral epithelial dysplasiaoral squamous cell carcinoma

Substanzen

Biomarkers, Tumor

Autor:innen und Institutionen

  • Department of Biomedical Engineering, Khalifa University, Abu Dhabi, United Arab Emirates.
  • Centre for Biomedical Engineering, School of Mechanical Engineering Sciences, University of Surrey, Surrey, UK.
  • Department of Electrical Engineering and Electronics, University of Liverpool, Liverpool, UK.
  • University College London, UCL Eastman Dental Institute, London, UK.
  • Head and Neck Surgery, University College London Hospital (UCLH), London, UK.
  • Regional Maxillofacial Unit, Queen Elizabeth University Hospital, Glasgow, UK.

ORCID-Profile: Valeria Mercadante, Stefano Fedele

Förderung

  • Invention for Innovation Programme
  • National Institute for Health Research
  • UCLH Biomedical Research Centre
  • National Institute for Health and Care Research

Zitieren

APA

Hughes, M. P., Labeed, F. H., Hoettges, K. F., Porter, S., Mercadante, V., Kalavrezos, N., Liew, C., McCaul, J. A., Kulkarni, R., Cymerman, J., Kerawala, C., Barber, J., Lewis, M. P., & Fedele, S. (2023). Point‐of‐care Analysis for Non‐invasive Diagnosis of Oral cancer ( PANDORA ): A technology‐development proof of concept diagnostic accuracy study of dielectrophoresis in patients with oral squamous cell carcinoma and dysplasia. Journal of Oral Pathology & Medicine. https://doi.org/10.1111/jop.13417

Vancouver

Hughes MP, Labeed FH, Hoettges KF, Porter S, Mercadante V, Kalavrezos N, et al. Point‐of‐care Analysis for Non‐invasive Diagnosis of Oral cancer ( PANDORA ): A technology‐development proof of concept diagnostic accuracy study of dielectrophoresis in patients with oral squamous cell carcinoma and dysplasia. Journal of Oral Pathology & Medicine. 2023. doi:10.1111/jop.13417

BibTeX
@article{Hughes2023,
  author = {Hughes, Michael P and Labeed, Fatima H and Hoettges, Kai F and Porter, Stephen and Mercadante, Valeria and Kalavrezos, Nicholas and Liew, Colin and McCaul, James A and Kulkarni, Raghav and Cymerman, James and Kerawala, Cyrus and Barber, Julie and Lewis, Mark P and Fedele, Stefano},
  title = {Point‐of‐care Analysis for Non‐invasive Diagnosis of Oral cancer ( PANDORA ): A technology‐development proof of concept diagnostic accuracy study of dielectrophoresis in patients with oral squamous cell carcinoma and dysplasia},
  journal = {Journal of Oral Pathology & Medicine},
  year = {2023},
  doi = {10.1111/jop.13417}
}
Kostenlos starten →